scispace - formally typeset
K

Keith James

Researcher at University of Edinburgh

Publications -  168
Citations -  5698

Keith James is an academic researcher from University of Edinburgh. The author has contributed to research in topics: Antibody & Immunotherapy. The author has an hindex of 39, co-authored 162 publications receiving 5349 citations. Previous affiliations of Keith James include Western General Hospital.

Papers
More filters
Journal ArticleDOI

BCG Immunotherapy of Bladder Cancer: 20 Years On

TL;DR: The cause of bladder cancer is unknown, but the disease has been strongly associated with exposure to certain aromatic chemicals, notably aniline dyes and benzidine compounds.
Journal ArticleDOI

Human monoclonal antibody production: Current status and future prospects

TL;DR: The development of human monoclonal antibody technology has been a slow, laborious and often unrewarding exercise, but in spite of the many problems encountered to date work has continued unabated, sustained by the widely held belief that this technology would result in improved diagnostics and therapeutics and would increase the understanding of human biology.
Journal ArticleDOI

Interactions between cytokines and α2-macroglobulin

TL;DR: The interaction between α 2 -macroglobulin and a number of cytokines has recently come under scrutiny, revealing a new and potentially important mechanism for the modulation of cytokine activity, while in the following paper a modulatory role for anti-cytokine antibodies is considered.
Journal ArticleDOI

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

Brian J. Willett, +672 more
- 07 Jul 2022 - 
TL;DR: In this article , the authors demonstrate substantial evasion of neutralization by Omicron BA.1 and BA.2 variants in vitro using sera from individuals vaccinated with ChAdOx1, BNT162b2 and mRNA-1273.529.
Journal ArticleDOI

Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall.

TL;DR: The main findings on immunohistochemical analysis were the universal induction of MHC Class II antigens by urothelial cells which was statistically significant up to 6 months after completion of therapy, coupled with a T cell dominated cystitis.